399 related articles for article (PubMed ID: 30550367)
1. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
[TBL] [Abstract][Full Text] [Related]
2. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Li J; Stagg NJ; Johnston J; Harris MJ; Menzies SA; DiCara D; Clark V; Hristopoulos M; Cook R; Slaga D; Nakamura R; McCarty L; Sukumaran S; Luis E; Ye Z; Wu TD; Sumiyoshi T; Danilenko D; Lee GY; Totpal K; Ellerman D; Hötzel I; James JR; Junttila TT
Cancer Cell; 2017 Mar; 31(3):383-395. PubMed ID: 28262555
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
4. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
[TBL] [Abstract][Full Text] [Related]
5. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
6. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.
Yadav R; Sukumaran S; Zabka TS; Li J; Oldendorp A; Morrow G; Reyes A; Cheu M; Li J; Wallin JJ; Tsai S; Sun L; Wang P; Ellerman D; Spiess C; Polson A; Stefanich EG; Kamath AV; Ovacik MA
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631556
[TBL] [Abstract][Full Text] [Related]
9. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K; Zuch de Zafra CL; Schutt LK; Clark V; Zhong F; Hristopoulos M; Clark R; Li J; Mathieu M; Chen X; Johnston J; Low J; Ybarra R; Slaga D; Yang J; Ovacik M; Dybdal NO; Totpal K; Junttila MR; Ellerman D; Lee G; Dennis MS; Prell R; Junttila TT
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271166
[TBL] [Abstract][Full Text] [Related]
10. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
11. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
13. IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion.
Li J; Clark R; Slaga D; Avery K; Liu K; Schubbert S; Varma R; Chiang E; Totpal K; Bernett MJ; Holder PG; Junttila TT
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38739434
[TBL] [Abstract][Full Text] [Related]
14. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
Kamakura D; Asano R; Kawai H; Yasunaga M
Cancer Immunol Immunother; 2021 Jan; 70(1):177-188. PubMed ID: 32666260
[TBL] [Abstract][Full Text] [Related]
16. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
17. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
[TBL] [Abstract][Full Text] [Related]
18. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
19. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
20. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
